IRISH

K1 Investment Management, LLC (“K1”) Statement regarding Possible Offer for MariaDB plc (“MariaDB”)

Retrieved on: 
Freitag, Februar 16, 2024

LOS ANGELES, Feb. 16, 2024 (GLOBE NEWSWIRE) -- K1 confirms that it made, on 15 February 2024, a non-binding proposal to the board of directors of MariaDB (the “Board”) to acquire, together with K1’s investment affiliates, all of the issued, and to be issued, share capital of MariaDB at a value of $0.55 per share (the “Possible Offer”). The terms of the Possible Offer represent:-

Key Points: 
  • THERE CAN BE NO CERTAINTY THAT ANY OFFER WILL BE MADE, NOR AS TO THE TERMS ON WHICH ANY SUCH OFFER WILL BE MADE.
  • K1 has a high regard for the MariaDB business and looks forward to engaging with MariaDB in connection with the Possible Offer.
  • However, K1 reserves the right to implement the proposal, instead, by way of contractual offer.
  • There can be no certainty that any offer will be made, nor as to the terms on which any such offer might be made.

Form 8 (OPD) - Irish Residential Properties REIT plc

Retrieved on: 
Dienstag, Januar 30, 2024

For a trust, the trustee(s), settlor and beneficiaries must be named.

Key Points: 
  • For a trust, the trustee(s), settlor and beneficiaries must be named.
  • (c) Name of offeror/offeree in relation to whose relevant securities this form relates:
    (d) Is the discloser the offeror or the offeree?
  • (f) In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer?
  • If it is a cash offer or possible cash offer, state “N/A”
    If there are interests and positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.

Commencement of Strategic Review

Retrieved on: 
Montag, Januar 8, 2024

The Company today announces that the Board of Directors of I-RES (the “Board”) has decided to commence a strategic review to consider and evaluate all strategic options that may be available to maximise and unlock value for shareholders in the Company (the “Strategic Review”).

Key Points: 
  • The Company today announces that the Board of Directors of I-RES (the “Board”) has decided to commence a strategic review to consider and evaluate all strategic options that may be available to maximise and unlock value for shareholders in the Company (the “Strategic Review”).
  • This Strategic Review will commence as soon as practicable in Q1 2024, following the release of the Company’s 2023 Full Year Financial Results.
  • The Special Committee will retain specialist international financial and real estate advice to assist with the Strategic Review.
  • There is no certainty that any change will result from the Strategic Review or that any sale, strategic investment or other transaction will be concluded, nor as to the terms on which any offer, strategic investment or other transaction may be made.

Runa Capital II (GP) (“Runa”) No intention to make an offer for MariaDB plc (“MariaDB”) and potential bridge loan of up to US$26.5 million

Retrieved on: 
Dienstag, Oktober 10, 2023

Dublin, Ireland, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Runa confirmed today that it does not intend to make an offer for MariaDB. Accordingly, Runa will be bound by the restrictions set out in Rule 2.8 of the Irish Takeover Rules. Runa reserves the right within the next 6 months to set aside this announcement where so permitted under Rule 2.8 (including 2.8(c)(ii)).

Key Points: 
  • Accordingly, Runa will be bound by the restrictions set out in Rule 2.8 of the Irish Takeover Rules.
  • Runa reserves the right within the next 6 months to set aside this announcement where so permitted under Rule 2.8 (including 2.8(c)(ii)).
  • Runa also announces that an associate of Runa intends to enter into an agreement with MariaDB regarding the provision of a three month bridge loan of up to US$26.5 million.
  • The content of this website is not incorporated into and does not form part of this announcement.

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

Retrieved on: 
Dienstag, Oktober 17, 2023

OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER

Key Points: 
  • OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER
    Owner or controller of interests and short positions disclosed, if different from 1(a)
    The naming of nominee or vehicle companies is insufficient.
  • For a trust, the trustee(s), settlor and beneficiaries must be named.
  • If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree (Note 1)
    For an opening position disclosure, state the latest practicable date prior to the disclosure
    In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer?
  • If it is a cash offer or possible cash offer, state “N/A”
    If there are interests and short positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

Retrieved on: 
Dienstag, Oktober 17, 2023

OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER

Key Points: 
  • OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER
    Owner or controller of interests and short positions disclosed, if different from 1(a)
    The naming of nominee or vehicle companies is insufficient.
  • For a trust, the trustee(s), settlor and beneficiaries must be named.
  • If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree (Note 1)
    For an opening position disclosure, state the latest practicable date prior to the disclosure
    In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer?
  • If it is a cash offer or possible cash offer, state “N/A”
    If there are interests and short positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

Retrieved on: 
Mittwoch, Oktober 4, 2023

OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER

Key Points: 
  • OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER
    Owner or controller of interests and short positions disclosed, if different from 1(a)
    The naming of nominee or vehicle companies is insufficient.
  • For a trust, the trustee(s), settlor and beneficiaries must be named.
  • If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree (Note 1)
    For an opening position disclosure, state the latest practicable date prior to the disclosure
    In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer?
  • If it is a cash offer or possible cash offer, state “N/A”
    If there are interests and short positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.

Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)

Retrieved on: 
Dienstag, Oktober 3, 2023

DEALING DISCLOSURE UNDER RULE 8.1(c) AND (d)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022

Key Points: 
  • DEALING DISCLOSURE UNDER RULE 8.1(c) AND (d)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022
    (a) Full name of discloser:
    (b) Owner or controller of interests and short positions disclosed, if different from 1(a):
    The naming of nominee or vehicle companies is insufficient.
  • For a trust, the trustee(s), settlor and beneficiaries must be named.
  • (c) Name of offeror/offeree in relation to whose relevant securities this form relates:
    (d) Status of person making the disclosure:
    Person acting in concert with the offeree (namely, a sibling of a director of the offeree)
    (f) In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer?
  • If it is a cash offer or possible cash offer, state “N/A”
    If there are positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.

Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)

Retrieved on: 
Dienstag, Oktober 3, 2023

DEALING DISCLOSURE UNDER RULE 8.1(c) AND (d)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022

Key Points: 
  • DEALING DISCLOSURE UNDER RULE 8.1(c) AND (d)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022
    (a) Full name of discloser:
    (b) Owner or controller of interests and short positions disclosed, if different from 1(a):
    The naming of nominee or vehicle companies is insufficient.
  • For a trust, the trustee(s), settlor and beneficiaries must be named.
  • (c) Name of offeror/offeree in relation to whose relevant securities this form relates:
    (d) Status of person making the disclosure:
    Person acting in concert with the offeree (namely, a director of the offeree)
    (f) In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer?
  • If it is a cash offer or possible cash offer, state “N/A”
    If there are positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

Retrieved on: 
Dienstag, Oktober 3, 2023

OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER

Key Points: 
  • OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER
    Owner or controller of interests and short positions disclosed, if different from 1(a)
    The naming of nominee or vehicle companies is insufficient.
  • For a trust, the trustee(s), settlor and beneficiaries must be named.
  • If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree (Note 1)
    For an opening position disclosure, state the latest practicable date prior to the disclosure
    In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer?
  • If it is a cash offer or possible cash offer, state “N/A”
    If there are interests and short positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.